Press Release

Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses

SAN DIEGOOctober 25, 2018 – Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a new patent from the United States Patent Office (USPTO). Patent Number: 10,105,436 “Smallpox Vaccine for Cancer Treatment” covers the use of oncolytic vaccinia viruses with adipose stromal (stem) cells for the treatment of solid tumors or hematologic malignancies. Calidi Biotherapeutics is currently developing a novel immunotherapy approach utilizing oncolytic vaccinia virus delivered via cell-based therapeutic platforms. The adipose stromal cells play an important role in protecting and potentiating oncolytic viruses, as have been demonstrated in Calidi’s pre-clinical research with oncolytic vaccinia virus.

“We are excited to be granted this patent based on the combination of oncolytic vaccinia viruses and adipose-derived stem cells,” said Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics. “We will continue to expand and protect our proprietary cell-based delivery platforms as we believe that stem cells will provide a superior delivery system for oncolytic virus-based therapies both now and in the future.”

“This patent is the culmination of many years of research and hard work focused on potentiating the oncolytic virus treatments of cancer. Quick elimination of oncolytic viruses by the patient’s immune system has been a major obstacle, and our new cell-based delivery platforms have the potential to overcome this difficulty, leading to an enhanced therapeutic efficacy,” said Boris Minev, MD, President, Medical and Scientific Affairs, Calidi Biotherapeutics.

Calidi Biotherapeutics is advancing its cell-based oncolytic virus platform in an Investigational New Drug (IND) application for the treatment of prostate cancer, based on previous guidance the company has received from the Food and Drug Administration (FDA) and Calidi’s scientific, clinical and regulatory expert advisors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is at the forefront of oncolytic virus-based immunotherapies for cancer, and is a clinical-stage drug development company with proprietary technology that overcomes the challenge to effective delivery of oncolytic viruses. The company’s research could transform the way that cancer is treated. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

INVESTOR CONTACT:
Stephen Thesing 
Senior Vice President, Corporate Development & Operations
bd@calidibio.com 

Contact: 
Aimee Eucce
aeucce@calidibio.com

http://www.calidibio.com